Clinical Trial

STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

Name: STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL) — clinical trial record (NCT07743138)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ACC or PPGL.

Trial Details

NCT Number	NCT07743138
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: Summit Therapeutics
Conditions	Phase II, Ivonescimab, Evaluate, Unresectable/Metastatic Adrenocortical Carcinoma, ACC, Unresectable Pheochromocytoma, PPGL
Enrollment	20 participants
Start Date	2027-02-07
Primary Completion	2028-05-01 (estimated)
Study Completion	2030-05-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-03